title: Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence.
abstract: This review represents the focus of a symposium that was presented at the "Alcoholism and Stress: A Framework for Future Treatment Strategies" conference in Volterra, Italy on May 3-6, 2011 and organized/chaired by Dr. Brendan M. Walker. The primary goal of the symposium was to evaluate and disseminate contemporary findings regarding the emerging role of kappa-opioid receptors (KORs) and their endogenous ligands dynorphins (DYNs) in the regulation of escalated alcohol consumption, negative affect and cognitive dysfunction associated with alcohol dependence, as well as DYN/KOR mediation of the effects of chronic stress on alcohol reward and seeking behaviors. Dr. Glenn Valdez described a role for KORs in the anxiogenic effects of alcohol withdrawal. Dr. Jay McLaughlin focused on the role of KORs in repeated stress-induced potentiation of alcohol reward and increased alcohol consumption. Dr. Brendan Walker presented data characterizing the effects of KOR antagonism within the extended amygdala on withdrawal-induced escalation of alcohol self-administration in dependent animals. Dr. Georgy Bakalkin concluded with data indicative of altered DYNs and KORs in the prefrontal cortex of alcohol dependent humans that could underlie diminished cognitive performance. Collectively, the data presented within this symposium identified the multifaceted contribution of KORs to the characteristics of acute and chronic alcohol-induced behavioral dysregulation and provided a foundation for the development of pharmacotherapeutic strategies to treat certain aspects of alcohol use disorders.
authors.affiliation: Laboratory of Alcoholism and Addictions Neuroscience, Department of Psychology and Graduate Program in Neuroscience, Alcohol and Drug Abuse Research Program, Translational Addiction Research Center, Washington State University, Pullman, WA 99164, USA. b_walker@wsu.edu
authors.forename: Brendan M
authors.initials: BM
authors.lastname: Walker
authors.forename: Glenn R
authors.initials: GR
authors.lastname: Valdez
authors.forename: Jay P
authors.initials: JP
authors.lastname: McLaughlin
authors.forename: Georgy
authors.initials: G
authors.lastname: Bakalkin
mesh_terms: D000437:Alcoholism / Q000188:drug therapy / Q000503:physiopathology* / Q000523:psychology; D000679:Amygdala / Q000187:drug effects* / Q000503:physiopathology; D000818:Animals; D004195:Disease Models, Animal; D004399:Dynorphins / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use; D000431:Ethanol / Q000494:pharmacology*; D006801:Humans; D018377:Neurotransmitter Agents / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use; D017473:Receptors, Opioid, kappa / Q000819:agonists / Q000502:physiology*; D013315:Stress, Psychological / Q000150:complications*; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D018377:Neurotransmitter Agents; D017473:Receptors, Opioid, kappa; D000431:Ethanol; D004399:Dynorphins